A New Approach to AUB

Our initial product will be targeted as a treatment or AUB in women who are finished having children, as an alternative to hysterectomy or endometrial ablation. However, Impres technology can be applied in a number of different ways and we expect that multiple product extensions and additional markets will be addressable once this initial technology is developed further.

Our initial product is currently in IRB controlled human clinical feasibility trials. This product has not been reviewed by the FDA and is not approved for use or evaluation in the United States.